Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이향운 | * |
dc.date.accessioned | 2018-12-14T16:31:02Z | - |
dc.date.available | 2018-12-14T16:31:02Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 1059-1311 | * |
dc.identifier.other | OAK-22536 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247790 | - |
dc.description.abstract | Purpose: To compare controlled-release carbamazepine monotherapy (CBZ-CR) with lamotrigine and valproate combination therapy (LTG + VPA) in equivalent total drug load, as initial drug regimen in untreated patients with partial and/or generalized tonic-clonic seizures (GTCS). Methods: This unblinded, randomized, 60-week superiority trial recruited patients having two or more unprovoked seizures with at least one seizure during previous three months. After randomization into CBZ-CR or LTG + VPA, patients entered into eight-week titration phase (TP), followed by 52-week maintenance phase (MP). Median doses of CBZ-CR and LTG + VPA were 600 mg/day and 75 mg/day + 500 mg/day, respectively. Primary outcome measure was completion rate (CR), a proportion of patients who have completed the 60-week study as planned. Secondary efficacy measures included seizure-free rate (SFR) for 52-week of MP and time to first seizure (TTFS) during MP. Results: Among 207 randomized patients, 202 underwent outcome analysis (104 in CBZ-CR, 98 in LTG + VPA). CR was 62.5% in CBZ-CR and 65.3% in LTG + VPA (p = 0.678). SFR during MP was higher in LTG + VPA (64.1%) than CBZ-CR (47.8%) (P = 0.034). TTFS was shorter with CBZ-CR (p = 0.041). Incidence of adverse effects (AEs) were 57.7% in CBZ-CR and 60.2% in LTG + VPA and premature drug withdrawal rates due to AEs were 12.5% and 7.1%, respectively, which were not significantly different. Conclusion: CR was comparable between LTG + VPA and CBZ-CR, however, both SFR for 52-week MP and TTFS during MP were in favor of LTG + VPA than CBZ-CR. The study suggested that LTG + VPA can be an option as initial drug regimen for untreated patients with partial seizures and/or GTCS except for women of reproductive age. © 2017 British Epilepsy Association | * |
dc.description.sponsorship | GlaxoSmithKline | * |
dc.language | English | * |
dc.publisher | W.B. Saunders Ltd | * |
dc.subject | CBZ-CR | * |
dc.subject | Combination therapy | * |
dc.subject | Initial drug regimen | * |
dc.subject | LTG + VPA | * |
dc.subject | Monotherapy | * |
dc.title | Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy | * |
dc.type | Article | * |
dc.relation.volume | 55 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 17 | * |
dc.relation.lastpage | 24 | * |
dc.relation.journaltitle | Seizure | * |
dc.identifier.doi | 10.1016/j.seizure.2017.12.008 | * |
dc.identifier.wosid | WOS:000430644800004 | * |
dc.identifier.scopusid | 2-s2.0-85043358392 | * |
dc.author.google | Lee B.I. | * |
dc.author.google | No S.K. | * |
dc.author.google | Yi S.-D. | * |
dc.author.google | Lee H.W. | * |
dc.author.google | Kim O.J. | * |
dc.author.google | Kim S.H. | * |
dc.author.google | Kim M.K. | * |
dc.author.google | Kim S.E. | * |
dc.author.google | Kim Y.S. | * |
dc.author.google | Kim J.M. | * |
dc.author.google | Lee S.-J. | * |
dc.author.google | Shin D.J. | * |
dc.author.google | Park S.P. | * |
dc.author.google | Kim Y.I. | * |
dc.author.google | Heo K. | * |
dc.author.google | Cho Y.W. | * |
dc.author.google | Cho Y.-J. | * |
dc.author.google | Kim Y.N. | * |
dc.contributor.scopusid | 이향운(34667959700) | * |
dc.date.modifydate | 20240123091326 | * |